AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.
AstraZeneca: Mispriced Growth Following The Oncology Segment Success
AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage. DCF suggests limited upside under conservative assumptions, but peer-based multiples indicate substantial appreciation potential, supporting a GARP investment case.
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Astrazeneca (AZN) closed the most recent trading day at $91.56, moving +1.93% from the previous trading session.
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in global pharma. The bank says a wave of clinical readouts (and a high likelihood of success) positions AstraZeneca to benefit disproportionately as investors shift their attention away from US drug-pricing fears and back towards innovation.
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
